Cargando…

Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis

BACKGROUND: The current World Health Organization (WHO) pediatric tuberculosis dosing guidelines lead to suboptimal drug exposures. Identifying factors altering the exposure of these drugs in children is essential for dose optimization. Pediatric pharmacokinetic studies are usually small, leading to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galileya, Lufina Tsirizani, Wasmann, Roeland E., Chabala, Chishala, Rabie, Helena, Lee, Janice, Njahira Mukui, Irene, Hesseling, Anneke, Zar, Heather, Aarnoutse, Rob, Turkova, Anna, Gibb, Diana, Cotton, Mark F., McIlleron, Helen, Denti, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662720/ https://www.ncbi.nlm.nih.gov/pubmed/37988391 http://dx.doi.org/10.1371/journal.pmed.1004303

Ejemplares similares

Population pharmacokinetics of ethambutol in African children: a pooled analysis
por: Tikiso, Tjokosela, et al.
Publicado: (2022)

A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis
por: Wasmann, Roeland E., et al.
Publicado: (2023)

Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications
por: Tikiso, Tjokosela, et al.
Publicado: (2021)

Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations
por: Chabala, Chishala, et al.
Publicado: (2021)

Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial
por: Chabala, Chishala, et al.
Publicado: (2018)

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial
por: Waalewijn, Hylke, et al.
Publicado: (2023)

Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV
por: Chabala, Chishala, et al.
Publicado: (2023)

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020)

Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review
por: Jacobs, Tom G, et al.
Publicado: (2020)

Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis
por: van der Laan, Louvina E., et al.
Publicado: (2021)

Shorter treatment for non-severe tuberculosis in African and Indian children
por: Turkova, Anna, et al.
Publicado: (2022)

Dihydroartemisinin-piperaquine or sulphadoxine-pyrimethamine for the chemoprevention of malaria in children with sickle cell anaemia in eastern and southern Africa (CHEMCHA): a protocol for a multi-centre, two-arm, double-blind, randomised, placebo-controlled superiority trial
por: Nkosi-Gondwe, Thandile, et al.
Publicado: (2023)

Isoniazid preventive therapy-related adverse events among Malawian adults on antiretroviral therapy: A cohort study
por: Tsirizani-Galileya, Lufina, et al.
Publicado: (2022)

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
por: Zhang, C, et al.
Publicado: (2010)

Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV
por: Ford, Deborah, et al.
Publicado: (2018)

Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

Compensation of subjects for participation in biomedical research in resource – limited settings: a discussion of practices in Malawi
por: Nyangulu, Wongani, et al.
Publicado: (2019)

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
por: Rockwood, Neesha, et al.
Publicado: (2016)

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy
por: Svensson, Elin M., et al.
Publicado: (2017)

Constructing a representative in‐silico population for paediatric simulations: Application to HIV‐positive African children
por: Wasmann, Roeland E., et al.
Publicado: (2021)

Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children
por: Bienczak, Andrzej, et al.
Publicado: (2017)

Current research toward optimizing dosing of first-line antituberculosis treatment
por: McIlleron, Helen, et al.
Publicado: (2018)

Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin‐resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2022)

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis
por: Gafar, Fajri, et al.
Publicado: (2023)

Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis
por: Rockwood, Neesha, et al.
Publicado: (2017)

Tuberculosis: opportunities and challenges for the 90–90–90 targets in HIV-infected children
por: Rabie, Helena, et al.
Publicado: (2015)

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2021)

A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug–Drug Interactions With Antiretroviral and Antituberculosis Treatment
por: Francis, Jose, et al.
Publicado: (2021)

Pharmacometrics: Opportunity for Reducing Disease Burden in the Developing World: The Case of Africa
por: Pillai, G, et al.
Publicado: (2013)

Tuberculosis caseload in children with severe acute malnutrition related with high hospital based mortality in Lusaka, Zambia
por: Munthali, Tendai, et al.
Publicado: (2017)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial
por: Mulenga, Veronica, et al.
Publicado: (2016)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Erratum to: Knowledge and perceptions of asthma in Zambia: a cross-sectional survey
por: Marsden, Emilia Jumbe, et al.
Publicado: (2016)

Knowledge and perceptions of asthma in Zambia: a cross-sectional survey
por: Jumbe Marsden, Emilia, et al.
Publicado: (2016)

Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus‐associated tuberculosis
por: Schutz, Charlotte, et al.
Publicado: (2020)

Pediatric tuberculosis: clinical and epidemiological reflections from a highly endemic setting
por: Hesseling, Anneke
Publicado: (2010)

Defeating Paediatric Tuberculous Meningitis: Applying the WHO “Defeating Meningitis by 2030: Global Roadmap”
por: Basu Roy, Robindra, et al.
Publicado: (2021)

Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies
por: Wasmann, Roeland E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6i4jn85qsfjnq0g50nat3nuung